Letter to the Editor: Serum bile acid profiling for diabetic gastrointestinal neuropathy: Promise and pitfalls

Abstract

The study published in the World Journal of Diabetes by Zhu et al explores a critical gap in diabetic care by investigating serum bile acid (BA) profiles in diabetic gastrointestinal autonomic neuropathy (DGAN). Their analysis identifies an altered BA profile in DGAN, with taurolithocholic acid (TLCA) emerging as a key discriminator. They report that a model combining TLCA with age and fasting C-peptide achieves an exceptionally high area under the curve of 0.970 for predicting DGAN risk. This editorial appraises these compelling yet preliminary findings, acknowledging the novel link between BA dysregulation-potentially via TGR5 pathways-and DGAN pathogenesis. However, significant methodological limitations necessitate caution. The remarkably high predictive performance is likely over-optimized due to the small DGAN cohort (n = 26), and the cross-sectional design cannot establish causality. Crucially, the association is profoundly confounded by disease severity and insulin use, and the exclusion of patients on first-line therapies (metformin, GLP-1 RAs) limits generalizability. While this research posits BA profiling as a promising tool for DGAN risk stratification, it remains hypothesis-generating. The findings mandate rigorous validation in large, prospective, multi-center cohorts before any clinical application can be considered.

Key Words: TGR5 receptor; Biomarker; Taurolithocholic acid; Bile acids; Diabetic gastroparesis; Diabetic autonomic neuropathy; Type 2 diabetes mellitus

Core Tip: This article critically appraises a novel study linking altered bile acid profiles, specifically taurolithocholic acid, to diabetic gastrointestinal autonomic neuropathy (DGAN). While the findings are biologically plausible and suggest a promising diagnostic model, significant limitations exist. The small sample size, cross-sectional design, and confounding by disease severity and treatment necessitate caution. The results are hypothesis-generating and underscore the need for large-scale validation before this potential biomarker can be considered for clinical risk stratification of DGAN.

TO THE EDITOR

The landscape of diabetic complications is vast, yet certain territories remain frustratingly obscure. Diabetic gastrointestinal autonomic neuropathy (DGAN) is one such domain. Characterized by a spectrum of debilitating symptoms-from nausea and vomiting to constipation and diarrhea-DGAN significantly impairs quality of life and is notoriously difficult to diagnose and manage[1]. The diagnostic gold standards, such as gastric emptying scintigraphy, are often inaccessible, expensive, and poorly correlated with symptom severity, creating a pressing need for non-invasive, pathophysiologically relevant biomarkers[2].

In this context, the study published in the World Journal of Diabetes by Zhu et al[3] represents a timely and intriguing investigation. The authors venture beyond conventional risk factors to explore the intricate world of bile acid (BA) metabolism, proposing that a specific BA profile, particularly involving taurolithocholic acid (TLCA), could be a key discriminator for DGAN risk. This editorial will dissect the study’s contributions, explore its mechanistic plausibility, highlight its significant limitations, and outline the essential steps required to translate these hypothesis-generating findings into clinical utility.

The core findings and their clinical allure

Zhu et al[3] reported a progressive suppression of conjugated BAs in type 2 diabetes that deepens in patients with DGAN. Using multivariate analysis, TLCA was identified as the most significant BA distinguishing the groups. The most striking reported result is a predictive nomogram combining TLCA, age, and fasting C-peptide, which demonstrated an exceptional area under the curve (AUC) of 0.970. From a clinical standpoint, these findings are alluring. The prospect of a simple blood test to stratify DGAN risk promises a move away from cumbersome functional tests towards earlier, mechanism-based risk assessment.

Mechanistic plausibility: Linking BAs to enteric neuropathy

The study’s significance is amplified by its attempt to root correlations in biology. BAs are now recognized as potent signaling molecules that activate specific receptors, most notably the G protein-coupled BA receptor TGR5[4]. TLCA is a high-affinity TGR5 ligand[5]. The proposed mechanism is elegant: TLCA, via TGR5 activation, can stimulate GLP-1 release and, more directly, TGR5 expressed on enteric neurons exerts anti-inflammatory and neuroprotective effects, influencing gut motility[6,7]. In murine models, TGR5 signaling is required for normal defecation[8]. Therefore, a deficiency in TLCA could theoretically permit enteric inflammation and impaired neuronal function, contributing to DGAN. This provides a plausible, though unproven, pathway connecting BA alteration to DGAN pathophysiology.

Critical limitations and the peril of overinterpretation

Despite its promise, the study by Zhu et al[3] carries limitations that necessitate cautious interpretation. From a clinical and methodological perspective, these findings must be scrutinized before considering any clinical application.

“Small n” problem and overfitting: The most significant limitation is the very small DGAN cohort (n = 26). While LASSO regression was used, an AUC of 0.970 in such a small cohort is almost certainly over-optimistic and will almost certainly degrade upon external validation in larger, independent, and more heterogeneous populations[9]. Such near-perfect discrimination is rare in biological systems and strongly suggests model overfitting.

Cross-sectional design and causality: The design prevents causal inference. We cannot determine whether altered BA profiles cause, result from, or simply coincide with DGAN. A compelling alternative explanation is reverse causation: DGAN-induced gut dysmotility can lead to small intestinal bacterial overgrowth, a condition known to drastically alter BA deconjugation and reduce TLCA levels. Thus, the observed BA profile could be a consequence, not a cause, of DGAN. Furthermore, unmeasured confounders like gut microbiome composition, which differs in DGAN and profoundly influences BA metabolism, could be the true mediator of the association.

Confounding by disease severity and treatment: The sensitivity analysis showing insulin use as the strongest predictor of DGAN (odds ratio = 54.73) is critical. While the authors suggest overadjustment, this finding robustly supports the alternative hypothesis: The observed BA alterations are a correlate of advanced, insulin-requiring diabetes (marked by β-cell failure and severe metabolic dysregulation), rather than a specific biomarker for DGAN per se. The association of TLCA with DGAN attenuated when insulin was adjusted for. Additionally, the exclusion of patients on metformin and GLP-1 receptor agonists-first-line T2DM therapies that significantly influence BA metabolism and gut motility-severely limits generalizability. This exclusion means the proposed biomarker was derived from and may only be relevant to an atypical, treatment-naïve subset of patients, questioning its utility in real-world clinical practice where these medications are ubiquitous.

TLCA concentration paradox and mechanistic evidence gap: Circulating TLCA is nanomolar, while in vitro TGR5 activation often requires micromolar concentrations. The explanation that local enterohepatic concentrations are higher is plausible but remains speculative. Crucially, there is a lack of direct human evidence: No studies measure BA concentrations in proximity to enteric neurons in DGAN patients or demonstrate impaired TGR5 signaling in their gut tissue, making the proposed mechanistic link a speculative leap from correlation to biology.

Diagnostic criteria and spectrum of DGAN: The reliance on gastroparesis-focused criteria for a pan-enteric disorder is a limitation. DGAN encompasses a broad spectrum of symptoms (e.g., gastroparesis, constipation, diarrhea). It is unclear if the TLCA-based model, developed in a gastroparesis-enriched cohort, would perform well in patients with predominant colonic or intestinal dysmotility, potentially limiting its diagnostic scope.

Future directions: From correlation to causation and clinic

So, where do we go from here? The work by Zhu et al[3] is not an endpoint but a starting point. It successfully generates a strong and biologically plausible hypothesis that should be rigorously tested through the following avenues. First, large-scale, multi-center validation is needed. The immediate next step is to validate the predictive nomogram in a large, prospective, multi-center cohort that includes patients on standard T2DM medications. This will provide a true, and likely more modest, estimate of its diagnostic accuracy. Second, longitudinal and interventional studies are required. Prospective cohorts that serially collect serum and clinical data from patients with T2DM can determine if a decline in TLCA (and other BAs) precedes the development of DGAN symptoms. Interventional studies, perhaps with BA sequestrants or TGR5 agonists (if safe and available), could provide causal evidence. If modulating the BA pool alters DGAN risk or symptoms, it would powerfully corroborate this link. Third, deep phenotyping and mechanistic exploration should be integrated. Future studies should integrate multi-omics approaches. Correlating serum BA profiles with fecal BA excretion, gut microbiome composition, and markers of intestinal inflammation and barrier function would provide a more holistic picture. If feasible, analysis of intestinal biopsies for TGR5 and FXR expression patterns in patients with and without DGAN would be invaluable. Fourth, exploring the gut-brain-liver axis could yield broader insights. DGAN is a manifestation of a systemic autonomic neuropathy. Investigating how BA signaling interacts with the vagus nerve and central autonomic centers could uncover broader pathophysiological mechanisms linking diabetes, the gut, and the nervous system[10].

CONCLUSION

The study by Zhu et al[3] is a commendable investigation that highlights a neglected complication and an underexplored metabolic pathway. It compellingly suggests that the serum BA profile, particularly TLCA, is altered in DGAN and holds diagnostic promise. However, we must temper enthusiasm with caution. The small sample size, cross-sectional design, profound confounding, and limited generalizability mean these findings are preliminary. The reported exceptional model performance is almost certainly an overestimate. Furthermore, translating BA profiling into routine practice faces practical hurdles, as these assays are not yet standardized or widely available for clinical use, raising questions about cost-effectiveness and accessibility. In conclusion, this study does not provide a ready-made test for DGAN. Instead, it provides a robust hypothesis that challenges the field to explore the interplay of metabolism, enterohepatic circulation, and neuro-immune function in diabetic complications. Through rigorous validation and extension of this work, we may eventually unlock new diagnostic and therapeutic strategies for patients suffering from DGAN.